Results 11 to 20 of about 588,711 (254)

Synergy between the pay‐for‐performance scheme and better physician–patient relationship might reduce the risk of retinopathy in patients with type 2 diabetes

open access: yesJournal of Diabetes Investigation, 2021
Aims/Introduction This study investigated whether participation by patients with type 2 diabetes in Taiwan’s pay‐for‐performance (P4P) program and maintaining good continuity of care (COC) with their healthcare provider reduced the likelihood of future ...
Shang‐Jyh Chiou   +4 more
doaj   +1 more source

The effect of ‘paying for performance’ on the management of type 2 diabetes mellitus: a cross-sectional observational study

open access: yesBJGP Open, 2020
Background: The ‘cycle of care’ (COC) pay for performance (PFP) programme, introduced in 2015, has resourced Irish GPs to provide structured care to PCRS eligible patients with type 2 diabetes mellitus (T2DM).
Raymond O'Connor   +6 more
doaj   +1 more source

Association of Clinician Health System Affiliation With Outpatient Performance Ratings in the Medicare Merit-based Incentive Payment System.

open access: yesJournal of the American Medical Association (JAMA), 2020
Importance Integration of physician practices into health systems composed of hospitals and multispecialty practices is increasing in the era of value-based payment.
K. Johnston   +4 more
semanticscholar   +1 more source

Early Enrollment in Diabetes Pay-for-Performance Program Reduced Loss of Life Expectancy in Newly-Diagnosed Patients with Type 2 Diabetes Mellitus [PDF]

open access: yesDiabetes & Metabolism Journal
Background Diabetes is associated with reduced lifespan. To explore pay-for-performance (P4P) program and life expectancy (LE), we investigated the impact of interval between diabetes diagnosis and enrollment in P4P program on loss-of-LE among patients ...
Yu-Ching Chen   +4 more
doaj   +1 more source

Do hospitals respond to changing incentive structures? Evidence from Medicare's 2007 DRG restructuring.

open access: yesJournal of Health Economics, 2020
In 2007, the Centers for Medicare and Medicaid restructured the diagnosis related group (DRG) system by expanding the number of categories within a DRG to account for complications present within certain conditions.
Amanda C. Cook, Susan L. Averett
semanticscholar   +1 more source

How can Saudi Arabia reform its public hospital payment models? A narrative review

open access: yesSaudi Pharmaceutical Journal, 2020
Background: The cost of Saudi healthcare continues to rise at an alarming rate, putting the sustainability of the public healthcare system into question.
Yazed AlRuthia   +3 more
doaj   +1 more source

Compensation and Incentives in Medical Networks with Gate-keeping and Case Management [PDF]

open access: yes, 2008
New approaches in health care, such as e.g. Integrated Delivery Systems, affect the role and tasks of medical suppliers. More and more, medical suppliers are incorporated into the process of guiding patients to medical specialists and hospitals and thus ...
Schumacher, Petra
core   +2 more sources

Recent advances in addressing the market failure of new antimicrobials: Learnings from NICE's subscription-style payment model

open access: yesFrontiers in Medical Technology, 2023
BackgroundAntimicrobial resistance (AMR) is a growing threat to global health. With pathogenic bacteria inevitably becoming more resistant to existing antimicrobials, mortality and costs due to AMR will significantly increase over the next few decades if
Marieke Schurer   +5 more
doaj   +1 more source

Understanding the Public Policy of Global Budget Payment Reform Improves the Quality of Public Healthcare From the Perspective of Patients in China

open access: yesFrontiers in Psychology, 2022
The transformation from the retrospective to the prospective payment system is significant to improve the quality of public healthcare (QPH). This article used the quasi-natural experiment of the global budget payment reform of government (GBPRG) in ...
Lele Li, Shuo Zhang
doaj   +1 more source

Pricing and reimbursement of orphan drugs: the need for more transparency

open access: yesOrphanet Journal of Rare Diseases, 2011
Pricing and reimbursement of orphan drugs are an issue of high priority for policy makers, legislators, health care professionals, industry leaders, academics and patients.
Simoens Steven
doaj   +1 more source

Home - About - Disclaimer - Privacy